The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-10-01

AUTHORS

Johan Jendle, M. I. Buompensiere, A. L. Holm, S. de Portu, S. J. P. Malkin, O. Cohen

ABSTRACT

IntroductionSwedish National Diabetes Registry data show a correlation of improved glycemic control in people with type 1 diabetes (T1D) with increased use of diabetes technologies over the past 25 years. However, novel technologies are often associated with a high initial outlay. The aim of the present study was to evaluate the long-term cost-effectiveness of the advanced hybrid closed-loop (AHCL) MiniMed 780G system versus intermittently scanned continuous glucose monitoring (isCGM) plus self-injection of multiple daily insulin (MDI) or continuous subcutaneous insulin infusion (CSII) in people with T1D in Sweden.MethodsOutcomes were projected over patients’ lifetimes using the IQVIA CORE Diabetes Model (v9.0). Clinical data, including changes in glycated hemoglobin (HbA1c) and hypoglycemia rates, were sourced from observational studies and a randomized crossover trial. Modeled patients were assumed to receive the treatments for their lifetimes, with HbA1c kept constant following the application of treatment effects. Costs were accounted from a societal perspective and expressed in Swedish krona (SEK). Utilities and days off work estimates were taken from published sources.ResultsThe MiniMed 780G system was associated with an improvement in life expectancy of 0.16 years and an improvement in quality-adjusted life expectancy of 1.95 quality-adjusted life years (QALYs) versus isCGM plus MDI or CSII. These clinical benefits were due to a reduced incidence and a delayed time to onset of diabetes-related complications. Combined costs were estimated to be SEK 727,408 (EUR 72,741) higher with MiniMed 780G, with treatment costs partially offset by direct cost savings from the avoidance of diabetes-related complications and indirect cost savings from the avoidance of lost workplace productivity. The MiniMed 780G system was associated with an incremental cost-effectiveness ratio of SEK 373,700 per QALY gained.ConclusionsBased on a willingness-to-pay threshold of SEK 500,000 per QALY gained, the MiniMed 780G system was projected to be cost-effective versus isCGM plus MDI or CSII for the treatment of T1D in Sweden. More... »

PAGES

2977-2991

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-021-01157-0

DOI

http://dx.doi.org/10.1007/s13300-021-01157-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1141559513

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34596879


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Medical Sciences, Campus US\u00d6, \u00d6rebro University, 701 82, \u00d6rebro, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.15895.30", 
          "name": [
            "Institute of Medical Sciences, Campus US\u00d6, \u00d6rebro University, 701 82, \u00d6rebro, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jendle", 
        "givenName": "Johan", 
        "id": "sg:person.0641671052.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641671052.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.471158.e", 
          "name": [
            "Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buompensiere", 
        "givenName": "M. I.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medtronic Denmark, Copenhagen, Denmark", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medtronic Denmark, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holm", 
        "givenName": "A. L.", 
        "id": "sg:person.016547144473.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016547144473.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.471158.e", 
          "name": [
            "Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Portu", 
        "givenName": "S.", 
        "id": "sg:person.01364766511.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364766511.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ossian Health Economics and Communications, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Malkin", 
        "givenName": "S. J. P.", 
        "id": "sg:person.012067446720.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.471158.e", 
          "name": [
            "Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "O.", 
        "id": "sg:person.0630134452.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630134452.57"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11136-014-0712-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041603789", 
          "https://doi.org/10.1007/s11136-014-0712-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-11-90", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013049175", 
          "https://doi.org/10.1186/1477-7525-11-90"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13410-020-00887-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1132498430", 
          "https://doi.org/10.1007/s13410-020-00887-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-009-0166-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030579838", 
          "https://doi.org/10.1007/s10198-009-0166-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-008-1089-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031888268", 
          "https://doi.org/10.1007/s00125-008-1089-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200220001-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011371263", 
          "https://doi.org/10.2165/00019053-200220001-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-0500-4-251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042011348", 
          "https://doi.org/10.1186/1756-0500-4-251"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200927010-00008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048836923", 
          "https://doi.org/10.2165/00019053-200927010-00008"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-10-01", 
    "datePublishedReg": "2021-10-01", 
    "description": "IntroductionSwedish National Diabetes Registry data show a correlation of improved glycemic control in people with type 1 diabetes (T1D) with increased use of diabetes technologies over the past 25\u00a0years. However, novel technologies are often associated with a high initial outlay. The aim of the present study was to evaluate the long-term cost-effectiveness of the advanced hybrid closed-loop (AHCL) MiniMed 780G system versus intermittently scanned continuous glucose monitoring (isCGM) plus self-injection of multiple daily insulin (MDI) or continuous subcutaneous insulin infusion (CSII) in people with T1D in Sweden.MethodsOutcomes were projected over patients\u2019 lifetimes using the IQVIA CORE Diabetes Model (v9.0). Clinical data, including changes in glycated hemoglobin (HbA1c) and hypoglycemia rates, were sourced from observational studies and a randomized crossover trial. Modeled patients were assumed to receive the treatments for their lifetimes, with HbA1c kept constant following the application of treatment effects. Costs were accounted from a societal perspective and expressed in Swedish krona (SEK). Utilities and days off work estimates were taken from published sources.ResultsThe MiniMed 780G system was associated with an improvement in life expectancy of 0.16\u00a0years and an improvement in quality-adjusted life expectancy of 1.95 quality-adjusted life years (QALYs) versus isCGM plus MDI or CSII. These clinical benefits were due to a reduced incidence and a delayed time to onset of diabetes-related complications. Combined costs were estimated to be SEK 727,408 (EUR\u00a072,741) higher with MiniMed 780G, with treatment costs partially offset by direct cost savings from the avoidance of diabetes-related complications and indirect cost savings from the avoidance of lost workplace productivity. The MiniMed 780G system was associated with an incremental cost-effectiveness ratio of SEK\u00a0373,700 per QALY gained.ConclusionsBased on a willingness-to-pay threshold of SEK 500,000 per QALY gained, the MiniMed 780G system was projected to be cost-effective versus isCGM plus MDI or CSII for the treatment of T1D in Sweden.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-021-01157-0", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "continuous subcutaneous insulin infusion", 
      "multiple daily insulin", 
      "quality-adjusted life years", 
      "diabetes-related complications", 
      "advanced hybrid closed-loop system", 
      "incremental cost-effectiveness ratio", 
      "treatment of T1D", 
      "subcutaneous insulin infusion", 
      "life expectancy", 
      "type 1 diabetes", 
      "quality-adjusted life expectancy", 
      "health economic analysis", 
      "cost-effectiveness ratio", 
      "continuous glucose monitoring", 
      "diabetes registry data", 
      "hypoglycemia rates", 
      "hybrid closed-loop system", 
      "glycemic control", 
      "daily insulin", 
      "indirect cost savings", 
      "crossover trial", 
      "clinical benefit", 
      "insulin infusion", 
      "Swedish krona", 
      "registry data", 
      "IQVIA CORE", 
      "clinical data", 
      "observational study", 
      "direct cost savings", 
      "life years", 
      "type 1", 
      "societal perspective", 
      "glucose monitoring", 
      "treatment costs", 
      "diabetes technology", 
      "treatment effects", 
      "complications", 
      "T1D", 
      "patients", 
      "cost savings", 
      "isCGM", 
      "workplace productivity", 
      "combined cost", 
      "present study", 
      "treatment", 
      "high initial outlay", 
      "years", 
      "expectancy", 
      "diabetes", 
      "MethodsOutcomes", 
      "infusion", 
      "insulin", 
      "incidence", 
      "trials", 
      "hemoglobin", 
      "onset", 
      "study", 
      "people", 
      "Sweden", 
      "days", 
      "improvement", 
      "avoidance", 
      "aim", 
      "data", 
      "novel technology", 
      "control", 
      "benefits", 
      "rate", 
      "correlation", 
      "effect", 
      "utility", 
      "initial outlay", 
      "changes", 
      "monitoring", 
      "use", 
      "threshold", 
      "krona", 
      "willingness", 
      "ratio", 
      "time", 
      "analysis", 
      "system", 
      "cost", 
      "economic analysis", 
      "estimates", 
      "savings", 
      "model", 
      "perspective", 
      "source", 
      "work estimates", 
      "technology", 
      "lifetime", 
      "applications", 
      "outlays", 
      "core", 
      "productivity", 
      "G systems", 
      "closed-loop system"
    ], 
    "name": "The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden", 
    "pagination": "2977-2991", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1141559513"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-021-01157-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34596879"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-021-01157-0", 
      "https://app.dimensions.ai/details/publication/pub.1141559513"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_907.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-021-01157-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01157-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01157-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01157-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01157-0'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      21 PREDICATES      131 URIs      115 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-021-01157-0 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N524436e68af141fa833f0b73e49d676d
4 schema:citation sg:pub.10.1007/s00125-008-1089-6
5 sg:pub.10.1007/s10198-009-0166-1
6 sg:pub.10.1007/s11136-014-0712-x
7 sg:pub.10.1007/s13410-020-00887-4
8 sg:pub.10.1186/1477-7525-11-90
9 sg:pub.10.1186/1756-0500-4-251
10 sg:pub.10.2165/00019053-200220001-00005
11 sg:pub.10.2165/00019053-200927010-00008
12 schema:datePublished 2021-10-01
13 schema:datePublishedReg 2021-10-01
14 schema:description IntroductionSwedish National Diabetes Registry data show a correlation of improved glycemic control in people with type 1 diabetes (T1D) with increased use of diabetes technologies over the past 25 years. However, novel technologies are often associated with a high initial outlay. The aim of the present study was to evaluate the long-term cost-effectiveness of the advanced hybrid closed-loop (AHCL) MiniMed 780G system versus intermittently scanned continuous glucose monitoring (isCGM) plus self-injection of multiple daily insulin (MDI) or continuous subcutaneous insulin infusion (CSII) in people with T1D in Sweden.MethodsOutcomes were projected over patients’ lifetimes using the IQVIA CORE Diabetes Model (v9.0). Clinical data, including changes in glycated hemoglobin (HbA1c) and hypoglycemia rates, were sourced from observational studies and a randomized crossover trial. Modeled patients were assumed to receive the treatments for their lifetimes, with HbA1c kept constant following the application of treatment effects. Costs were accounted from a societal perspective and expressed in Swedish krona (SEK). Utilities and days off work estimates were taken from published sources.ResultsThe MiniMed 780G system was associated with an improvement in life expectancy of 0.16 years and an improvement in quality-adjusted life expectancy of 1.95 quality-adjusted life years (QALYs) versus isCGM plus MDI or CSII. These clinical benefits were due to a reduced incidence and a delayed time to onset of diabetes-related complications. Combined costs were estimated to be SEK 727,408 (EUR 72,741) higher with MiniMed 780G, with treatment costs partially offset by direct cost savings from the avoidance of diabetes-related complications and indirect cost savings from the avoidance of lost workplace productivity. The MiniMed 780G system was associated with an incremental cost-effectiveness ratio of SEK 373,700 per QALY gained.ConclusionsBased on a willingness-to-pay threshold of SEK 500,000 per QALY gained, the MiniMed 780G system was projected to be cost-effective versus isCGM plus MDI or CSII for the treatment of T1D in Sweden.
15 schema:genre article
16 schema:isAccessibleForFree true
17 schema:isPartOf N04d4f81f5d3e46ff85c63507cc9c08c8
18 N2aebf47e91ea449b8492f4ef234e63d6
19 sg:journal.1044057
20 schema:keywords G systems
21 IQVIA CORE
22 MethodsOutcomes
23 Sweden
24 Swedish krona
25 T1D
26 advanced hybrid closed-loop system
27 aim
28 analysis
29 applications
30 avoidance
31 benefits
32 changes
33 clinical benefit
34 clinical data
35 closed-loop system
36 combined cost
37 complications
38 continuous glucose monitoring
39 continuous subcutaneous insulin infusion
40 control
41 core
42 correlation
43 cost
44 cost savings
45 cost-effectiveness ratio
46 crossover trial
47 daily insulin
48 data
49 days
50 diabetes
51 diabetes registry data
52 diabetes technology
53 diabetes-related complications
54 direct cost savings
55 economic analysis
56 effect
57 estimates
58 expectancy
59 glucose monitoring
60 glycemic control
61 health economic analysis
62 hemoglobin
63 high initial outlay
64 hybrid closed-loop system
65 hypoglycemia rates
66 improvement
67 incidence
68 incremental cost-effectiveness ratio
69 indirect cost savings
70 infusion
71 initial outlay
72 insulin
73 insulin infusion
74 isCGM
75 krona
76 life expectancy
77 life years
78 lifetime
79 model
80 monitoring
81 multiple daily insulin
82 novel technology
83 observational study
84 onset
85 outlays
86 patients
87 people
88 perspective
89 present study
90 productivity
91 quality-adjusted life expectancy
92 quality-adjusted life years
93 rate
94 ratio
95 registry data
96 savings
97 societal perspective
98 source
99 study
100 subcutaneous insulin infusion
101 system
102 technology
103 threshold
104 time
105 treatment
106 treatment costs
107 treatment effects
108 treatment of T1D
109 trials
110 type 1
111 type 1 diabetes
112 use
113 utility
114 willingness
115 work estimates
116 workplace productivity
117 years
118 schema:name The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden
119 schema:pagination 2977-2991
120 schema:productId N8b4afaebfad44909ab02be73b9e2d370
121 N9ae915c9d50748d8b4769389afa43e54
122 Nae0727cf01744ee5ba108bd40eeef40c
123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141559513
124 https://doi.org/10.1007/s13300-021-01157-0
125 schema:sdDatePublished 2022-11-24T21:07
126 schema:sdLicense https://scigraph.springernature.com/explorer/license/
127 schema:sdPublisher N116ac7f8f0274ec085b2ac26bd8788bd
128 schema:url https://doi.org/10.1007/s13300-021-01157-0
129 sgo:license sg:explorer/license/
130 sgo:sdDataset articles
131 rdf:type schema:ScholarlyArticle
132 N04d4f81f5d3e46ff85c63507cc9c08c8 schema:issueNumber 11
133 rdf:type schema:PublicationIssue
134 N116ac7f8f0274ec085b2ac26bd8788bd schema:name Springer Nature - SN SciGraph project
135 rdf:type schema:Organization
136 N2aebf47e91ea449b8492f4ef234e63d6 schema:volumeNumber 12
137 rdf:type schema:PublicationVolume
138 N363c498e2bb64c05a46c899ef9e696cc rdf:first sg:person.0630134452.57
139 rdf:rest rdf:nil
140 N524436e68af141fa833f0b73e49d676d rdf:first sg:person.0641671052.00
141 rdf:rest Nf6768fe1842f40be957bdc6a9d09d138
142 N5ba950af452147e1b291c56811f84e8a rdf:first sg:person.016547144473.15
143 rdf:rest Ned121d8d15b943c083d23dc18c8e8191
144 N8ae73d5a7fc64063b3592093b10587c6 schema:affiliation grid-institutes:grid.471158.e
145 schema:familyName Buompensiere
146 schema:givenName M. I.
147 rdf:type schema:Person
148 N8b4afaebfad44909ab02be73b9e2d370 schema:name dimensions_id
149 schema:value pub.1141559513
150 rdf:type schema:PropertyValue
151 N9ae915c9d50748d8b4769389afa43e54 schema:name pubmed_id
152 schema:value 34596879
153 rdf:type schema:PropertyValue
154 Nae0727cf01744ee5ba108bd40eeef40c schema:name doi
155 schema:value 10.1007/s13300-021-01157-0
156 rdf:type schema:PropertyValue
157 Nd3f9b113d84f4f25aaa1ba3e21f738fa rdf:first sg:person.012067446720.22
158 rdf:rest N363c498e2bb64c05a46c899ef9e696cc
159 Ned121d8d15b943c083d23dc18c8e8191 rdf:first sg:person.01364766511.29
160 rdf:rest Nd3f9b113d84f4f25aaa1ba3e21f738fa
161 Nf6768fe1842f40be957bdc6a9d09d138 rdf:first N8ae73d5a7fc64063b3592093b10587c6
162 rdf:rest N5ba950af452147e1b291c56811f84e8a
163 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
164 schema:name Medical and Health Sciences
165 rdf:type schema:DefinedTerm
166 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
167 schema:name Clinical Sciences
168 rdf:type schema:DefinedTerm
169 sg:journal.1044057 schema:issn 1869-6953
170 1869-6961
171 schema:name Diabetes Therapy
172 schema:publisher Springer Nature
173 rdf:type schema:Periodical
174 sg:person.012067446720.22 schema:affiliation grid-institutes:None
175 schema:familyName Malkin
176 schema:givenName S. J. P.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22
178 rdf:type schema:Person
179 sg:person.01364766511.29 schema:affiliation grid-institutes:grid.471158.e
180 schema:familyName de Portu
181 schema:givenName S.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364766511.29
183 rdf:type schema:Person
184 sg:person.016547144473.15 schema:affiliation grid-institutes:None
185 schema:familyName Holm
186 schema:givenName A. L.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016547144473.15
188 rdf:type schema:Person
189 sg:person.0630134452.57 schema:affiliation grid-institutes:grid.471158.e
190 schema:familyName Cohen
191 schema:givenName O.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630134452.57
193 rdf:type schema:Person
194 sg:person.0641671052.00 schema:affiliation grid-institutes:grid.15895.30
195 schema:familyName Jendle
196 schema:givenName Johan
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641671052.00
198 rdf:type schema:Person
199 sg:pub.10.1007/s00125-008-1089-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031888268
200 https://doi.org/10.1007/s00125-008-1089-6
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s10198-009-0166-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030579838
203 https://doi.org/10.1007/s10198-009-0166-1
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s11136-014-0712-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041603789
206 https://doi.org/10.1007/s11136-014-0712-x
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s13410-020-00887-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132498430
209 https://doi.org/10.1007/s13410-020-00887-4
210 rdf:type schema:CreativeWork
211 sg:pub.10.1186/1477-7525-11-90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013049175
212 https://doi.org/10.1186/1477-7525-11-90
213 rdf:type schema:CreativeWork
214 sg:pub.10.1186/1756-0500-4-251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042011348
215 https://doi.org/10.1186/1756-0500-4-251
216 rdf:type schema:CreativeWork
217 sg:pub.10.2165/00019053-200220001-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011371263
218 https://doi.org/10.2165/00019053-200220001-00005
219 rdf:type schema:CreativeWork
220 sg:pub.10.2165/00019053-200927010-00008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048836923
221 https://doi.org/10.2165/00019053-200927010-00008
222 rdf:type schema:CreativeWork
223 grid-institutes:None schema:alternateName Medtronic Denmark, Copenhagen, Denmark
224 Ossian Health Economics and Communications, Basel, Switzerland
225 schema:name Medtronic Denmark, Copenhagen, Denmark
226 Ossian Health Economics and Communications, Basel, Switzerland
227 rdf:type schema:Organization
228 grid-institutes:grid.15895.30 schema:alternateName Institute of Medical Sciences, Campus USÖ, Örebro University, 701 82, Örebro, Sweden
229 schema:name Institute of Medical Sciences, Campus USÖ, Örebro University, 701 82, Örebro, Sweden
230 rdf:type schema:Organization
231 grid-institutes:grid.471158.e schema:alternateName Medtronic International Trading Sàrl, Tolochenaz, Switzerland
232 schema:name Medtronic International Trading Sàrl, Tolochenaz, Switzerland
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...